Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

4,100.00p
   
  • Change Today:
    -90.00p
  • 52 Week High: 4,500.00p
  • 52 Week Low: 3,800.00p
  • Currency: UK Pounds
  • Shares Issued: 5.21m
  • Volume: 2,251
  • Market Cap: £213.58m

Bioventix full-year revenue and profits improve

By Josh White

Date: Monday 21 Oct 2019

LONDON (ShareCast) - (Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue for the year on Monday, to £9.3m.
The AIM-traded firm said its profit before tax rose 1% in the year ended 30 June to £7m, while its cash fell £0.5m to £6.5m.

Its board declared a second interim dividend of 43p per share, up from 36p in the prior year, and a special dividend of 47p per share, down from 55p year-on-year.

"Looking ahead to the future, we keenly anticipate the roll-out of high sensitivity troponin assays and modest growth from additional vitamin D and other antibody sales and royalties," said the Bioventix board in its statement.

"Beyond that, growth will be linked not only to the troponin project but also our continued research activities as we look to seed additional projects that will germinate in the period 2025-2030 to create additional shareholder value."

As at 1113 BST, shares in Bioventix were down 4.24% at 3,409p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 4,100.00p
Change Today -90.00p
% Change -2.15 %
52 Week High 4,500.00p
52 Week Low 3,800.00p
Volume 2,251
Shares Issued 5.21m
Market Cap £213.58m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
86.81% below the market average86.81% below the market average86.81% below the market average86.81% below the market average86.81% below the market average
80.77% below the sector average80.77% below the sector average80.77% below the sector average80.77% below the sector average80.77% below the sector average
Price Trend
52.96% below the market average52.96% below the market average52.96% below the market average52.96% below the market average52.96% below the market average
49.15% below the sector average49.15% below the sector average49.15% below the sector average49.15% below the sector average49.15% below the sector average
Income Not Available
Growth
77.46% above the market average77.46% above the market average77.46% above the market average77.46% above the market average77.46% above the market average
16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average16.67% above the sector average

Bioventix Dividends

  Latest Previous
  1st Interim Special
Ex-Div 08-Apr-21 29-Oct-20
Paid 23-Apr-21 13-Nov-20
Amount 43.00p 53.00p

Trades for 23-Jun-2021

Time Volume / Share Price
15:53 5 @ 4,100.00p
15:46 9 @ 4,065.00p
15:42 109 @ 4,050.00p
15:39 105 @ 4,050.00p
15:32 371 @ 4,050.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page